EUCTR2006-006907-35-IT进行中（未招募）不适用
A multicenter, multinational, phase 3b, open label extension trial, to evaluate the long term effect of the 24 hour transdermal delivery of rotigotine on motor function, sleep quality, and nocturnal and non motor symptoms in subjects with idiopathic Parkinson disease. - SP915, Long term extension of RECOVER
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 270
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Subjects must fulfill the following inclusion criteria 1. Subject is informed and given ample time and opportunity to think about her/his participation and has given her/his written informed consent. 2. Subject is willing and able to comply with all trial requirements. 3. Subject has completed trial SP889. 4. Subject, in the opinion of the investigator, would benefit from long-term treatment of rotigotine.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Subjects are not permitted to enroll in the trial if any of the following criteria are met 1. Subject has an ongoing serious adverse event that is assessed as related to study medication
研究者
相似试验
进行中（未招募）
1 期
A multicenter, multinational, phase 3b, open-label extension trial to assess the safety and tolerability of long-term treatment of rotigotine patch in subjects with idiopathic Parkinson's diseaseParkinson's diseaseEUCTR2004-002641-12-GBSchwarz Biosciences GmbH220
进行中（未招募）
不适用
A multicenter, multinational, phase 3b, open-label extension trial to assess the safety and tolerability of long-term treatment of rotigotine patch in subjects with idiopathic Parkinson's diseaseParkinson's diseaseEUCTR2004-002641-12-ATSchwarz Biosciences GmbH220
进行中（未招募）
1 期
A multicenter, multinational, phase 3b, open-label extension trial to assess the safety and tolerability of long-term treatment of rotigotine patch in subjects with idiopathic Parkinson's diseaseParkinson's diseaseEUCTR2004-002641-12-ESSchwarz Biosciences GmbH220
进行中（未招募）
不适用
A multicenter, multinational, phase 3B, open-label extension trial to assess the safety and tolerability of long-term treatment of rotigotine patch in subjects with idiopathic Parkinson s diseaseEUCTR2004-002641-12-ITSCHWARZ PHARMA220
进行中（未招募）
不适用
A phase 3b, open-label, multicenter, multinational trial to evaluate the effects of rotigotine transdermal patch on early morning motor impairment and sleep disorders in patients with idiopathic Parkinson's diseaseParkinson's DiseaseEUCTR2004-002598-21-ATSchwarz Biosciences GmbH50